TScan Therapeutics, Inc. (NASDAQ: TCRX)

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company (NASDAQ: TCRT), operates in the biotechnology industry, specifically in the development of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of cancer patients. The company's main business activities revolve around learning from patients who are winning their fight against cancer to treat those who are not. TScan is building its ImmunoBank, a repository of therapeutic T cell receptors (TCRs) that recognize various targets and are associated with multiple human leukocyte antigen (HLA) types.

TScan generates revenue through the development and commercialization of its TCR-T therapies, which are designed to be used in combination with each other to treat and eliminate solid tumors. The company's primary products include TSC-100 and TSC-101, which are in development for the treatment of patients with hematologic malignancies, and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205, which are in development for the treatment of patients with solid tumors.

In the hematologic malignancies program, TScan is developing its therapies to treat patients with non-B cell malignancies, including acute myeloid leukemia, myelodysplastic syndromes, and acute lymphocytic leukemia, who are undergoing allogeneic hematopoietic cell transplantation. The company's lead TCR-T therapy candidates, TSC-100 and TSC-101, are designed to target HA-1 and HA-2, respectively, both of which are antigens with clinically demonstrated anti-tumor effects in patients who naturally develop T cells specific to these targets.

In the solid tumor program, TScan is developing a portfolio of autologous TCR-T therapy candidates that are designed to be used in combination with each other to treat and eliminate solid tumors. The company's TSC-200 series of product candidates are designed to elicit anti-tumor responses in patients by targeting cancer-specific antigens in their tumor cells. The first six solid tumor TCR-T therapy candidates include a combination of known targets, such as HPV16 for TSC-200, PRAME for TSC-203, and MAGE-A1 for TSC-204, as well as targets that are novel antigens for TCR-T therapy, such as for TSC-201, TSC-202, and TSC-205.

TScan's competitive advantage lies in its proprietary platform technologies, which enable the identification of novel antigens and clinically active TCRs. The company's TargetScan technology allows it to analyze the T cells of cancer patients who are responding to immunotherapy to identify the most active and clinically relevant TCRs against each target. TScan's ReceptorScan technology enables the identification of highly active TCRs that recognize clinically validated targets, and its SafetyScan technology allows it to identify potential off-target interactions of a given TCR and eliminate those TCR candidates that cross-react with proteins expressed at high levels in critical organs, reducing the risk of off-target effects.

TScan's position within the industry is as a leader in the development of engineered T cell therapies for the treatment of cancer. The company's proprietary platform technologies and expertise in T cell biology and immunology position it to develop a wide range of TCR-T therapies for the treatment of patients with hematologic malignancies and solid tumors.

TScan's customers include patients with cancer who are in need of innovative and effective treatments. The company's products are designed to be used in combination with each other to treat and eliminate solid tumors, and its customers will include patients with a variety of solid tumor types, including head and neck, cervical, non-small cell lung, ovarian, and melanoma.

The brand names and/or trade names of TScan's products and services include TSC-100, TSC-101, TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205.